We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+25.49%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$918M
AUM Growth
+$52.7M
Cap. Flow
-$46.8M
Cap. Flow %
-5.1%
Top 10 Hldgs %
48.26%
Holding
70
New
15
Increased
16
Reduced
21
Closed
16
Avg Time Held Equity + Options
0.5 years
Top 10 Avg Time Held Equity + Options
0.4 years
Top 20 Avg Time Held Equity + Options
0.4 years
Avg Time Held Equity only
0.5 years
Top 10 Avg Time Held Equity only
0.4 years
Top 20 Avg Time Held Equity only
0.4 years

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$38.1M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$29.8M
3
AZN icon
AstraZeneca
AZN
+$18.5M
4
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$18.5M
5
BIIB icon
Biogen
BIIB
+$13.9M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$39.5M
2
HCA icon
HCA Healthcare
HCA
+$23.2M
3
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$20.9M
4
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$18.8M
5
WCG
Wellcare Health Plans, Inc.
WCG
+$15.3M

Sector Composition

Rank Sector Weight
1 Healthcare 85.78%
2 Miscellaneous 9.3%
3 Technology 2.51%
4 Communication Services 1.69%
5 Financials 0.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
FOLD icon
1
DELISTED
Amicus Therapeutics
FOLD
$57.2M 6.23%
6,875,274
+1,168,368
+20% +$8.02M
2013 Q2
6 quarters
ARRY icon
2
DELISTED
Array Biopharma Inc
ARRY
$56.1M 6.11%
11,858,294
+3,516,249
+42% +$13.9M
2013 Q2
6 quarters
BHC icon
3
Bausch Health
BHC
$2.36B
$48.4M 5.27%
338,477
+5,910
+2% +$795K
2014 Q1
3 quarters
CMRX icon
4
DELISTED
Chimerix, Inc.
CMRX
$46.6M 5.07%
1,157,184
+36,152
+3% +$1.22M
2013 Q2
6 quarters
RAD
5
DELISTED
Rite Aid Corporation
RAD
$45.4M 4.94%
301,937
+38,901
+15% +$4.32M
2014 Q1
3 quarters
CLVS
6
DELISTED
Clovis Oncology, Inc.
CLVS
$40.4M 4.4%
721,632
-62,827
-8% -$3.3M
2013 Q2
6 quarters
RCPT
7
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$38.3M 4.17%
312,736
-127,142
-29% -$12.9M
2013 Q3
5 quarters
CELG
8
DELISTED
Celgene Corp
CELG
$38.3M 4.17%
342,349
-27,051
-7% -$2.85M
2014 Q3
1 quarter
ADVM icon
9
DELISTED
Adverum Biotechnologies
ADVM
$37.8M 4.11%
69,907
-39
-0.1% -$15K
2014 Q3
1 quarter
GILD icon
10
Gilead Sciences
GILD
$198B
$34.7M 3.78%
+368,615
New +$38.1M
2014 Q4
0 quarters
SGEN
11
DELISTED
Seagen Inc. Common Stock
SGEN
$31.6M 3.44%
983,966
+855,736
+667% +$29.8M
2014 Q3
1 quarter
TRIV
12
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
$22.1M 2.4%
1,755,568
+4,050
+0.2% +$55.2K
2014 Q2
2 quarters
ZSPH
13
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$21.8M 2.37%
524,702
+50,570
+11% +$2M
2014 Q3
1 quarter
TVTY
14
DELISTED
Tivity Health, Inc. Common Stock
TVTY
$21.2M 2.31%
1,068,489
+41,986
+4% +$686K
2013 Q3
5 quarters
LAB icon
15
Standard BioTools
LAB
$260M
$20.6M 2.24%
610,442
+50,820
+9% +$1.44M
2014 Q2
2 quarters
AZN icon
16
AstraZeneca
AZN
$261B
$18.2M 1.98%
+258,305
New +$18.5M
2014 Q4
0 quarters
MCK icon
17
McKesson
MCK
$116B
$18.2M 1.98%
87,523
-74,242
-46% -$15.1M
2014 Q3
1 quarter
PBYI icon
18
Puma Biotechnology
PBYI
$550M
$17.8M 1.93%
93,865
+42,840
+84% +$9.5M
2014 Q3
1 quarter
NSTG
19
DELISTED
NanoString Technologies, Inc.
NSTG
$17.6M 1.92%
1,266,538
-187,117
-13% -$2.28M
2013 Q3
5 quarters
ITCI icon
20
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$17.5M 1.9%
990,810
-12,686
-1% -$198K
2014 Q1
3 quarters
BLCM
21
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$17.3M 1.88%
+86,081
New +$18.5M
2014 Q4
0 quarters
NUVA
22
DELISTED
NuVasive, Inc.
NUVA
$16.9M 1.84%
358,679
-139,762
-28% -$5.83M
2013 Q2
6 quarters
HNT
23
DELISTED
HEALTH NET INC
HNT
$16.5M 1.8%
309,045
-25,890
-8% -$1.27M
2014 Q3
1 quarter
PRQR icon
24
ProQR Therapeutics
PRQR
$207M
$15.7M 1.71%
751,171
-14,061
-2% -$213K
2014 Q3
1 quarter
INSM icon
25
Insmed
INSM
$21.5B
$15.7M 1.71%
1,012,371
-78,253
-7% -$1.11M
2014 Q3
1 quarter
1
2 3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2014 Portfolio in Review

As of Q4 2014, Redmile Group held 70 positions worth $918M, up 6.1% from $866M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Redmile Group withdrew a net $46.8M in Q4 2014, closing 16 positions and reducing 21 holdings. Its most notable exit was Allergan plc, an estimated $39.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 76% a quarter earlier, followed by Miscellaneous and Technology.

Against the trend, Redmile Group opened a new position in Gilead Sciences worth $34.7M.

  • Redmile Group's largest Q4 2014 buy was Gilead Sciences: 368,615 shares worth $34.7M.
  • Redmile Group added most to Seagen Inc. Common Stock in Q4 2014, an estimated $29.8M increase.
  • Redmile Group's biggest Q4 2014 reduction was Wellcare Health Plans, Inc., cutting an estimated $15.3M.
  • Redmile Group fully exited Allergan plc in Q4 2014, selling an estimated $39.5M.
  • Redmile Group's ten largest holdings make up 48% of its $918M portfolio in Q4 2014.
  • Redmile Group opened 15 new positions and closed 16 in Q4 2014.
  • Redmile Group's portfolio value rose 6.1% quarter-over-quarter to $918M.

Based on Redmile Group's 13F filing for Q4 2014, filed 18 Feb 2015.